Histology
Non-Small Cell Carcinoma
CI-CAN-00001292Explore in graph →
1,752 active trials47 approved drugs589 evidence items
- NCIt
- C65151
Loading cancer entity…
Loading cancer entity…
Histology
CI-CAN-00001292Explore in graph →
Clinical trials
6,757 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,046)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03267654 | Gefitinib With Chemotherapy or Anti-angiogenesis in NSCLC Patients With Bim Deletion or Low EGFR Mutation Abundance | unknown | Phase 2 | 100 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 3, 2020 | clinicaltrials |
| NCT03758677 | Apatinib Combined With Chemotherapy for NSCLC Patients Without T790M Mutation | unknown | Phase 2 | 30 | The First Hospital of Jilin UniversityOTHER | 1 | Jul 23, 2020 | clinicaltrials |
| NCT04470076 | Neoadjuvant Afatinib Combination With Chemotherapy for Stage Ⅱa-Ⅲb NSCLC With EGFR Activating Mutation(Neoafa) | unknown | Phase 2 | 30 | Fifth Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 0 | Jul 14, 2020 | clinicaltrials |
| NCT03848611 | CM082 and JS001 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC). | unknown | Phase 2 | 20 | AnewPharmaINDUSTRY | 1 | Jul 9, 2020 | clinicaltrials |
| NCT04273815 | A Study to Evaluate the Tolerance, Pharmacokinetics and Efficacy of TQ-A3334 Tablets | unknown | Phase 1 / Phase 2 | 40 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Jul 8, 2020 | clinicaltrials |
| NCT01746251 | Adjuvant Afatinib in Stage I-III NSCLC With EGFR Mutation | unknown | Phase 2 | 92 | Massachusetts General HospitalOTHER | 1 | Jul 7, 2020 | clinicaltrials |
| NCT04459663 | JS001 Combination Therapy in NSCLC Negative Driving Gene After First-line Chemotherapy. | unknown | Phase 2 | 50 | Li Zhang, MDOTHER | 1 | Jul 7, 2020 | clinicaltrials |
| NCT04455594 | Almonertinib Vs. Erlotinib/Chemotherapy for Neo-adjuVant Treatment of Stage IIIA-N2 EGFR-mutated NSCLC(ANSWER) | unknown | Phase 2 | 168 | The First Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jul 2, 2020 | clinicaltrials |
| NCT02737774 | Alternating Icotinib and Chemotherapy for Advanced Non-small Cell Lung Cancer With EGFR Mutation | unknown | Phase 2 | 60 | Henan Cancer HospitalOTHER_GOV | 1 | Jul 1, 2020 | clinicaltrials |
| NCT04453423 | Combination Chemotherapy With or Without Anlotinib in the Maintenance Treatment of Non-Squamous Non-Small Cell Lung Cancer. | unknown | Phase 2 | 90 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 0 | Jul 1, 2020 | clinicaltrials |
| NCT03571360 | CTA Expression/Methylation and Response to Pembrolizumab of NSCLC Patients | unknown | Phase 2 | 42 | Medical University of ViennaOTHER | 1 | Jun 11, 2020 | clinicaltrials |
| NCT04425681 | Osimertinib With Bevacizumab for Leptomeningeal Metastasis From EGFR-mutation Non-Small Cell Lung Cancer(OWBLM) | unknown | Phase 2 | 20 | Second Affiliated Hospital of Nanchang UniversityOTHER | 1 | Jun 11, 2020 | clinicaltrials |
| NCT04371796 | Sintilimab (IBI308) in the Neoadjuvant Treatment of Patients With Resectable II-IIIA NSCLC | unknown | Phase 2 | 20 | Sichuan Cancer Hospital and Research InstituteOTHER | 0 | May 1, 2020 | clinicaltrials |
| NCT04358562 | Gefitinib With Anlotinib in Advanced Non-squamous NSCLC Patients With Uncleared Plasma ctDNA EGFRm After First-line Treatment With Gefitinib | unknown | Phase 2 | 240 | Second Affiliated Hospital of Nanchang UniversityOTHER | 1 | Apr 24, 2020 | clinicaltrials |
| NCT04339829 | An Open Label, Multicenter, Phase II Study of Dacomitinib for EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) With Brain Metastases | unknown | Phase 2 | 50 | Guangdong Association of Clinical TrialsOTHER | 0 | Apr 9, 2020 | clinicaltrials |
| NCT03706287 | Efficacy and Safety of Anlotinib Plus Platinum Plus Pemetrexed in T790M-negative NSCLC | unknown | Phase 1 / Phase 2 | 62 | Sichuan Cancer Hospital and Research InstituteOTHER | 1 | Apr 6, 2020 | clinicaltrials |
| NCT04333004 | Analysis of Gut Microbiota in Patients With Brain Metastasis of Non-small Cell Lung Cancer Treated by Pembrolizumab Combined With Chemotherapy | unknown | Phase 1 / Phase 2 | 40 | Xiaorong DongOTHER | 0 | Apr 3, 2020 | clinicaltrials |
| NCT03823625 | An Open-label, Randomized, Parallel, Non Comparative, Phase II Trial of Nivolumab Plus Ipilimumab Versus Platinum-based Chemotherapy Plus Nivolumab in Chemonaive Metastatic or Recurrent Squamous-Cell Lung Cancer (SqLC)(SQUINT) | unknown | Phase 2 | 112 | Fondazione Ricerca TraslazionaleOTHER | 1 | Mar 25, 2020 | clinicaltrials |
| NCT03119519 | Local Non-salvage Radiotherapy for Synchronous Oligometastatic Non-small-cell Lung Cancer. | unknown | Phase 2 | 148 | Southern Medical University, ChinaOTHER | 1 | Mar 18, 2020 | clinicaltrials |
| NCT04303130 | Camrelizumab Combined With Endostar for First-line Treatment in Subjects With Advanced Squamous NSCLC | unknown | Phase 2 | 52 | Peking University Cancer Hospital & InstituteOTHER | 1 | Mar 10, 2020 | clinicaltrials |
| NCT02583542 | A Study of AZD2014 in Combination With Selumetinib in Patients With Advanced Cancers(TORCMEK) | unknown | Phase 1 / Phase 2 | 118 | Queen Mary University of LondonOTHER | 1 | Feb 25, 2020 | clinicaltrials |
| NCT04284202 | PD-1 Combined With Dasatinib for as Third-line Treatment for ARID1A Mutation Advanced NSCLC | unknown | Phase 2 | 30 | The Affiliated Hospital of Qingdao UniversityOTHER | 1 | Feb 25, 2020 | clinicaltrials |
| NCT02725918 | Pemetrexed vs Pemetrexed Plus Cisplatin in EGFR-mutant NSCLC Patients After First Line EGFR-TKIs Failure | unknown | Phase 2 | 150 | Guangdong Association of Clinical TrialsOTHER | 1 | Feb 12, 2020 | clinicaltrials |
| NCT03557411 | A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Hypofraction Radiotherapy in Patients With NSCLC | unknown | Phase 2 | 42 | Shandong Cancer Hospital and InstituteOTHER | 1 | Feb 5, 2020 | clinicaltrials |
| NCT04252365 | Sintilimab Versus Pembrolizumab for Advanced-stage Non-Small-Cell Lung Cancer | unknown | Phase 2 | 20 | Guangdong Association of Clinical TrialsOTHER | 0 | Feb 5, 2020 | clinicaltrials |
| NCT04255836 | Durvalumab Combined With Chemotherapy and Stereotactic Body Radiotherapy (SBRT) in Patients With Oligometastatic Non-small Cell Lung Cancer (NSCLC) | unknown | Phase 2 | 35 | Zhejiang Cancer HospitalOTHER | 0 | Feb 5, 2020 | clinicaltrials |
| NCT01795521 | LungTech: Stereotactic Body Radiotherapy (SBRT) of Inoperable Centrally Located NSCLC(LungTech) | unknown | Phase 2 | 39 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 4 | Jan 31, 2020 | clinicaltrials |
| NCT04250246 | A Study of NIVO Plus IPI and Guadecitabine or NIVO Plus IPI in Melanoma and NSCLC Resistant to Anti-PD1/PDL1(NIBIT-ML1) | unknown | Phase 2 | 184 | Italian Network for Tumor Biotherapy FoundationOTHER | 1 | Jan 31, 2020 | clinicaltrials |
| NCT02416739 | Anticancer Activity of Nicotinamide on Lung Cancer | unknown | Phase 2 / Phase 3 | 110 | Il Yeong Park, Ph.D.OTHER | 1 | Jan 27, 2020 | clinicaltrials |
| NCT04239443 | Clinical Study of PD-1 Monoclonal Antibody SHR-1210 and Apatinib in Advanced NSCLC, Soft Tissue Sarcoma, and Uterine Cancer | unknown | Phase 2 | 120 | Hunan Cancer HospitalOTHER | 1 | Jan 27, 2020 | clinicaltrials |
| NCT03624309 | Anlotinib Plus Docetaxel for the Treatment of EGFR Wild-type Advanced Non-small-cell Lung Cancer | unknown | Phase 2 | 84 | Hunan Cancer HospitalOTHER | 1 | Jan 7, 2020 | clinicaltrials |
| NCT04213170 | Sintilimab Combined With Bevacizumab for Brain Metastases From Non-small Cell Lung Cancer | unknown | Phase 2 | 60 | Sun Yat-sen UniversityOTHER | 1 | Dec 30, 2019 | clinicaltrials |
| NCT04211896 | Anlotinib Combined With Nivolumab for Non-Small Cell Lung Cancer | unknown | Phase 2 | 70 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 0 | Dec 26, 2019 | clinicaltrials |
| NCT04199559 | Evaluating Combination Therapy Using Autologous Dendritic Cells Pulsed With Antigen Peptides and Nivolumab for Subjects With Advanced Non-Small Cell Lung Cancer | unknown | Phase 1 / Phase 2 | 30 | Henan Cancer HospitalOTHER_GOV | 1 | Dec 16, 2019 | clinicaltrials |
| NCT04193007 | The Role of Brain Radiotherapy in Patients With Asymptomatic Brain Metastasis in the Era of Targeted Therapy for NSCLC(BRATR) | unknown | Phase 2 | 100 | Second Affiliated Hospital of Nanchang UniversityOTHER | 1 | Dec 10, 2019 | clinicaltrials |
| NCT04182698 | Study of Anlotinib Plus Chemoradiotherapy in Patients With Locally Advanced NSCLC | unknown | Phase 1 / Phase 2 | 90 | Second Affiliated Hospital of Xi'an Jiaotong UniversityOTHER | 1 | Dec 2, 2019 | clinicaltrials |
| NCT04181372 | A Study of Neoadjuvant Chemotherapy Plus Anlotinib in Stage III(N2) Non-small-cell Lung Cancer | unknown | Phase 2 | 50 | The First Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Nov 29, 2019 | clinicaltrials |
| NCT04180501 | SRS Sequential Sindilimab in Brain Metastasis of NSLSC | unknown | Phase 2 | 25 | Xiaorong DongOTHER | 1 | Nov 27, 2019 | clinicaltrials |
| NCT04167774 | A Study to Evaluate Camrelizumab in Combination With Nb-Paclitaxel in Patients With Advanced or Metastatic NSCLC(Compass-001) | unknown | Phase 2 | 62 | Sun Yat-sen UniversityOTHER | 1 | Nov 22, 2019 | clinicaltrials |
| NCT04164745 | Efficacy and Safety Study of Anlotinib With Pembrolizumab in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Non-small Cell Lung Cancer | unknown | Phase 2 | 49 | Peking Union Medical College HospitalOTHER | 1 | Nov 15, 2019 | clinicaltrials |
| NCT02367443 | Hypofractionated Accelerated Radiotherapy With Concomitant Chemotherapy for NSCLC | unknown | Phase 1 / Phase 2 | 92 | Independent Public Care Health Facility of the Ministry of the Interior and Warmian & Mazurian Oncology CentreOTHER | 1 | Nov 6, 2019 | clinicaltrials |
| NCT04148898 | Osimertinib With or Without Bevacizumab for EGFR- Mutant Non-small Cell Lung Cancer With Leptomeningeal Metastasis(OWONBNSCLCLM) | unknown | Phase 2 | 80 | Second Affiliated Hospital of Nanchang UniversityOTHER | 0 | Nov 4, 2019 | clinicaltrials |
| NCT04056572 | Study of TQ-B3139 in Subjects With Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib | unknown | Phase 2 | 135 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Oct 30, 2019 | clinicaltrials |
| NCT04133337 | Apatinib Combined With SHR-1210 Injection in the Treatment of Patients With Removable IB-IIIA NSCLC | unknown | Phase 1 / Phase 2 | 20 | Sichuan Cancer Hospital and Research InstituteOTHER | 1 | Oct 21, 2019 | clinicaltrials |
| NCT04131543 | Phase II Study With Cabozantinib in Patients With RET Positive NSCLC(CRETA) | unknown | Phase 2 | 25 | University of BolognaOTHER | 1 | Oct 18, 2019 | clinicaltrials |
| NCT04124731 | Combination Therapy of Sintilimab and Anlotinib as a First-line Treatment in Advanced NSCLC (SUNRISE) | unknown | Phase 2 | 98 | Shanghai Chest HospitalOTHER | 0 | Oct 11, 2019 | clinicaltrials |
| NCT04111913 | A Study of Sequential Anlotinib Followed by EP Regimen Plus Concurrent Radiotherapy for Unresectable Stage III Non-small Cell Lung Cancer | unknown | Phase 2 | 100 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Oct 1, 2019 | clinicaltrials |
| NCT04108013 | A Study of SHR-1210 in Combination With Carboplatin+Paclitaxel-albumin in Subjects With Resectable NSCLC | unknown | Phase 2 | 38 | Xuanwu Hospital, BeijingOTHER | 0 | Sep 27, 2019 | clinicaltrials |
| NCT04106180 | SBRT in Combination With Sintilimab and GM-CSF for the Treatment of Advanced NSCLC | unknown | Phase 2 | 63 | Fudan UniversityOTHER | 1 | Sep 26, 2019 | clinicaltrials |
| NCT04054531 | Study of KN046 With Chemotherapy in First Line Advanced NSCLC | unknown | Phase 2 | 50 | Jiangsu Alphamab Biopharmaceuticals Co., LtdINDUSTRY | 1 | Sep 10, 2019 | clinicaltrials |
Data updated 23 days agoSource updated Aug 3, 2020source: clinicaltrials